Protagonist Therapeutics PTG-300 Opportunity Update Webinar

Virtual, September 11, 2020

Please join Protagonist Therapeutics (PTGX) for a PTG-300 Opportunity Update Webinar to discuss PTG-300 and its potential in patients with polycythemia vera. Event details including the KOL speakers can be found below. 

KOL Speakers:

Srdan Verstovsek, MD, PhD
Director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms
MD Anderson Cancer Center

Ronald Hoffman, MD
Director of the Myeloproliferative Diseases Program
The Icahn School of Medicine at Mount Sinai

 

RSVP for Event / Log Back in Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

Protagonist Therapeutics [PTGX] $1,139 MM MCap
Pro­pri­e­tary pep­tide tech­nol­o­gy plat­form to de­vel­op oral tar­get­ed ther­a­py-based drugs and in­jecta­bles for rare dis­eas­es. PTG-300 in­jectable hep­cidin mimet­ic Ph 2 trials on­go­ing in po­ly­cythemia ve­ra and hered­i­tary he­mochro­ma­to­sis; pos­i­tive up­dat­ed Ph 2 re­sults in PV pre­sent­ed at ASH 2020. PN-943 oral GI-re­strict­ed al­pha-4-be­ta-7 an­ta­g­on­ist Ph 2 in ul­cer­a­tive coli­tis study sites ac­ti­vat­ed; PTG-200, part­nered w/ Janssen, oral GI-re­strict­ed IL-23R an­ta­g­on­ist Ph 2 Crohn’s dis­ease study on­go­ing. [more in­for­ma­tion]